Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...

The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

The stock was trading down more than 5.5% at the time of writing following the revelation that in the REDEFINE 2 trial, CagriSema (cagrilintide and semaglutide) achieved a weight loss of 15.7% ...

On December 20, 2024, Novo announced headline results for its REDEFINE-1 trial ... "2.4 mg cagrilintide and 2.4 mg semaglutide once-weekly," the maximum dosage of CagriSema contemplated by ...

that gave a weight reduction of 22.7% for CagriSema versus 11.8% with cagrilintide alone, 16.1% with semaglutide, and 2.3% with placebo. The design of REDEFINE-1 allowed patients to lower their ...

Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") of a class action securities lawsuit.

Now, with Kalki 2 in development, reports suggest that Amitabh Bachchan’s character will have an extended screen presence, making his role even more pivotal to the unfolding saga. Amitabh ...

The company said a Phase 3 trial showed that after 68 weeks, those who took CagriSema achieved a weight loss of 15.7%, compared with a weight loss of 3.1% for those taking a placebo. Tomi Kilgore ...